“Nobody ever got anywhere by listening to no.”
Amy Ripka is the founder and CEO of Lucy Therapeutics. She is designing a new class of mitochondrial-based therapies for Rett Syndrome and other neurological diseases.
Ripka previously developed drugs to treat infection, cancer, and cardiovascular disease. She is also a member of the scientific advisory boards of Q Biomed Ventures and Caraway Therapeutics.
She received her B.A. in chemistry and music from Northwestern University and Ph.D. in organic chemistry and medicinal chemistry at the University of Wisconsin-Madison. She completed her postdoctoral studies at Scripps Research under Nobel Laureate K. Barry Sharpless.